COVID-19 pneumonia.
Conditions
Interventions
Intervention 1: Intervention group: Concomitant with the national corona treatment recommendation (hydroxychloroquine + lopinavir/ritonavir), patients will receive interferon beta, sub type 1a (CinnaG
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients with highly suspected or confirmed COVID-19 infection who are candid forhospitalized and starting triple-drug combination
Exclusion criteria
Exclusion criteria: History of drug allergy Uncontrolled baseline diseases including neuropsychiatric disorders, diabetes, thyroid disorders, heart disease Pregnancy and lactation Baseline liver failure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response to the treatment. Timepoint: Daily. Method of measurement: According the clinical, paraclinical and laboratory findings.;Complications of the treatment. Timepoint: Daily. Method of measurement: Interview and patient's record. | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of hospitalization. Timepoint: End of the treatment. Method of measurement: Patient's record.;Clinical outcome. Timepoint: End of treatment. Method of measurement: Patient's record. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHossein Khalili
Tehran University of Medical Sciences
Outcome results
None listed